



## ASX ANNOUNCEMENT

7 September 2021

### RESULTS OF GENERAL MEETING

---

**7 September 2021** - Cann Group Limited (the **Company**) is pleased to advise the results of today's General Meeting of shareholders.

All resolutions contained in the Notice of Meeting were decided on a poll and were approved. In particular, each of the resolutions, being ordinary resolutions, were approved by a majority of the votes cast by shareholders entitled to vote and voting on each resolution.

In accordance with Listing Rule 3.13.2 and section 251AA(1) of the Corporations Act, the results of the General Meeting are set out in the attached report and include a summary of the poll voting results and votes by proxies on each resolution considered at the General Meeting.

**Authorised for release by Geraldine Farrell, Company Secretary, Cann Group Limited.**

**For all media enquiries please contact:**

Matthew Wright  
NWR Communications  
+61 451 896 420  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

**For all other information please contact:**

Peter Crock CEO Cann Group Limited +61 3 9095 7088 <a href="mailto:contact@canngrouponlimited.com">contact@canngrouponlimited.com</a>	Clive Fanning Head of Investor Relations Cann Group Limited +61 3 9095 7088 <a href="mailto:clive.fanning@canngrouponlimited.com">clive.fanning@canngrouponlimited.com</a>
---	--

**About Cann Group**

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: [www.canngrouponlimited.com](http://www.canngrouponlimited.com) | [www.satipharm.com](http://www.satipharm.com)

# CANN GROUP LIMITED

# RESULT OF GENERAL MEETING 2021 (ASX REPORT)



GENERAL MEETING 2021  
Tuesday, 7 September, 2021

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	Result
1	RATIFICATION OF ISSUE OF SHARES UNDER PLACEMENT	NA	39,140,420 93.16%	1,236,911 2.95%	1,636,211 3.89%	269,058	41,238,232 97.06%	1,247,111 2.94%	276,625	Carried
2A	APPROVAL OF PROPOSED PLACEMENT OF SHARES TO ALLAN MCCALLUM	NA	34,683,554 90.99%	1,871,051 4.91%	1,562,688 4.10%	210,306	36,692,843 95.10%	1,891,251 4.90%	222,873	Carried
2B	APPROVAL OF PROPOSED PLACEMENT OF SHARES TO PHILIP JACOBSEN	NA	34,431,223 90.76%	1,878,264 4.95%	1,628,459 4.29%	225,135	36,506,283 95.06%	1,898,464 4.94%	237,702	Carried
2C	APPROVAL OF PROPOSED PLACEMENT OF SHARES TO DOUG RATHBONE	NA	40,825,641 93.83%	1,876,204 4.32%	806,108 1.85%	213,066	42,078,350 95.69%	1,896,404 4.31%	225,633	Carried
2D	APPROVAL OF PROPOSED PLACEMENT OF SHARES TO GEOFF PEARCE	NA	40,847,803 92.26%	1,869,771 4.23%	1,555,959 3.51%	209,066	42,850,363 95.78%	1,889,971 4.22%	221,633	Carried
2E	APPROVAL OF PROPOSED PLACEMENT OF SHARES TO JOHN SHARMAN	NA	40,765,474 92.08%	1,884,600 4.26%	1,623,459 3.66%	209,066	42,835,534 95.74%	1,904,800 4.26%	221,633	Carried
3	RATIFICATION OF SHARES ISSUED TO CSIRO	NA	40,503,429 94.99%	562,841 1.32%	1,572,798 3.69%	167,998	42,540,395 98.67%	573,041 1.33%	172,998	Carried
4	RATIFICATION OF SHARES ISSUED IN RESPECT OF THE ACQUISITION OF THE SATIPHARM BUSINESS	NA	42,142,913 95.16%	583,478 1.32%	1,557,679 3.52%	198,529	44,174,960 98.70%	583,478 1.30%	203,529	Carried
5	APPROVAL OF SHARES TO BE ISSUED IN RESPECT OF THE ACQUISITION OF THE SATIPHARM BUSINESS	NA	42,002,348 94.87%	702,661 1.59%	1,568,116 3.54%	209,474	44,044,832 98.43%	702,661 1.57%	214,474	Carried
6	APPROVAL OF SHARE PURCHASE PLAN OFFER (SPP)	NA	38,752,771 93.97%	915,305 2.22%	1,570,835 3.81%	3,243,688	40,782,774 97.76%	935,505 2.24%	3,243,688	Carried

\*\* - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item